Prucalopride (Resolor®, Movetis) is a selective high affinity 5-HT4 receptor agonist that facilitates cholinergic and excitatory nonadrenergic, noncholinergic neurotransmission . The drug is orally active and acts via a systemic mechanism initiating high amplitude propagated contractions (HAPCs) in the colon .
It enhances colonic propulsion and accelerates right colon emptying . Prucalopride also accelerates gastric emptying and small bowel transit (Bouras et al. 2001). This review seeks to assess the scientific rationale for using prucalopride in chronic constipation and to discuss the current evidence for its role in the management of chronic constipation..
Although the pathogenesis of both normal and slow transit constipation is incompletely understood, there is plenty of evidence to develop serotonin-4 (5-HT4) receptor agonists in the treatment of chronic constipation as they accelerate transit, increase stool frequency, and improve stool consistency